Member Info for The_Paladin

Could the inhalation of nebulised IFN-β be applied in the treatment of MS? Has this been considered by Synairgen as part of their aspiration in moving towards developing their product as a broad spectrum treatment?

“The renewed interest in IFN biology related to viral infections has led to a deeper knowledge on the effects of these molecules on the immune system, which could be rapidly translated into practice thanks to solid experience in the MS field.”

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1161849/full

It is probably best to green bin the short term sellers on this forum. It is obvious who they are!

One thing is certain. The market shenanigans that have surrounded this investment are not serving the best of interest of those of us who are adopting a long term hold strategy.

I can think of three occasions when I would have benefited enormously from selling “high” and buying back “low”.

It is probably high time for this company to deliver on its promises! LTHs have been on hold for a very long time. I am not in a poor position with this investment. However, to say that I am disappointed that promises given to investors have not yet been met in line with the company’s promoted

“expectations” is an important understatement!

My SNG investment “strategy” is, and always was, that described by Doc83 and Wigster. However, I would not recommend it to other investors, as their affairs are none of my business. Every investor presumably carries out their own research, and takes decisions based on the conclusions of that research.

My decision to hold all my SNG portfolio throughout the SNG0018 trial was a mistake. However, a long time ago, I decided that research concerning SNG001 conducted prior to the outcome of that trial wasn’t flawed.

I was under informed as to the company’s revised strategy until recently. Although nothing is certain, I am now relatively “optimistic” that we are back on track. Although far from being secure, my long term hold (3 years next August since my first shares purchase) has a chance of future success again. My thanks to everyone who reported back from the AGM. The detailed commentary on its proceedings, and on the nature of the next P2 trials, were invaluable in updating my knowledge about, and understanding of the company’s strategy.

Future success is a long term prospect. I am currently considering a time frame of at least another year, if not longer. The only issue that currently blights my horizon is that of funding. Despite the fact that the initial trials are funded from the company’s capital reserve, future funding remains uncertain? IMHO, successful readouts from the P2 trials should go a long way in securing future support? Like all investors, I will need to be patient and see what develops?

The LTIs, who gave up on Synairgen sold their holdings a long time ago. Any investors, who didn’t sell when the share price was in the 25p - 35p range last year are highly unlikely to do so now? It is far better to risk losing it all than to sell at the current price IMHO. Especially, if like me you believe that the share price will recover to a far higher level than is the case today?

I have been reading the latest company information carefully, and have consigned my SNG portfolio to the bottom drawer, probably until late 2024 - 2025. It is going to take a considerable time for the current strategy to fully evolve. Some support may be needed along the way? Or perhaps a different direction may be taken by the company if the P2 results show promise? Spacman’s prophecies may yet come to fruition? Who knows?

Any sensible investor would not dismiss SNG001 on the grounds that it is too expensive. The potential benefits of administering the drug would need to be carefully weighed against other available options for a particular situation.

Expert opinions testify that there is a need for an effective broad spectrum antiviral treatment. Statistics are quoted on the Synairgen website, and on multiple LinkedIn accounts.

Successful P2 trials could pave the way for its emergence as a necessary component of the vast toolkit of essential treatments?

There is a long wait ahead of us to be sure. It is best to avoid the meaningless comments from the unbelievers, purveyors of extreme negativity, and prophets of doom. They know as much and as little as I do about what the future may hold?

GLALTIs

The capital letters are being changed to lower case in my posts this morning? Is anyone else experiencing the same?

strange to see ********* for r.e.t.a.r.d.ing in my previous post? perhaps the inappropriate language filter originated in the usa? the word has a more offensive meaning over there.

glaltis.

this investment is heading in the right direction. this morning, we are seeing profit taking from traders, which is ******ing a more significant rise as a result of some buyers, who have decided to come on board.

more evidence is needed to tempt significant buyers and impart momentum on the share price rise. a matter of time imho, but i have little idea how long it will take before the share price will reach 0.25p (when i shall sell some of my shares)?

glaltis.

My thanks to all who attended the AGM for providing feedback. I have been out all day, and haven't yet had the time to read your comments. That will happen during the weekend.

I followed this board on my iPhone for part of the morning. In retrospect, I believe that some of my comments at the time were hasty, and badly-judged. Having looked at the presentation in greater detail, I now have a better understanding of Synairgen's strategy. It is going to take far longer than I had originally anticipated for the company to start making progress, but I am now happier with our situation than I have been for several months. The major issue, as I see it will be in securing appropriate funding to carry this research through to a conclusion. It is far too early to think about Phase III trials. For the time being, there is sufficient capital to commence with the initial parallel trials.

I am hoping that the coming year will be a better one for the company than the preceeding one. It is useful for investors to finally have an idea of the company's future direction.

GLALTIs.

The same thing is happening as during the debacle of the P2 Home Trial Webinar. They got away with that one, for obvious reasons.

Sadly, the CEO and his acolytes do not learn from past mistakes. His new year message gave the impression of being thrown together with little effort. These presentation slides are the same. They are similar to what are currently appearing in abundance on LinkedIn and elsewhere. They are not Synairgen specific. What happened to the corporate image that Brooke Clarke built on twitter/LinkedIn?

Meanwhile, their presentation is being accompanied by significant sells!

One wonders how long the company’s lack of real progress will continue? Surely they are not going to waste more time in presenting at conferences this coming season? High time for them to roll up their sleeves and get on with some real work!

Additionally, it is probably the right time for the 2021 hires, in anticipation of commercialisation in 2022, to leave the stage? Enough is enough!

Rant over!

Attendees at today’s AGM are being given a presentation on stratified medicine by Prof Sir Stephen Holgate, and Dr. Monk. The slides are displayed on the Synairgen website.

At the very end, they state that they are preparing to commence the trials ‘this coming Winter’! As one of the most cynical contributors to this forum, I am getting a sense of deja vu from that last phrase! I trust that something will actually happen this time around? Our friends at the AGM will no doubt gauge the sentiment of the Synairgen team, and share with us later.

GLALTIs.

It didn’t have anything to do with your rebuttal Docdaneeka. It was hold4results’ third post, which contained a crude sexual reference, that probably did it? When it was removed, your contribution, the next one in the thread, was also deleted.

The right outlets for hold4results’ disjointed ramblings probably exist somewhere in cyberspace? This forum is not one of them IMHO.

Well argued! A similar comment, but from a different angle, was offered on the bulletin board of a different company. It might equally apply to Synairgen?

“For the post Covid scenario in this sector, revenue trumps outstanding science and opportunity. Perhaps PI investment is now less speculative? This will turn again in time.”

GLA for tomorrow. In particular, to investors attending the AGM. I wish you all a good day, and a positive experience. Any feedback would be gratefully accepted.

"We are now working IN HASTE on discussions with platform trial organisers and investigators, as well as regulatory authorities, the pharmaceutical and biotech industry and government bodies to identify and establish the optimal method of conducting further trials to confirm these findings and move forward, not just for COVID-19, but also as a potential treatment for patients hospitalised due to a range of viruses including influenza, RSV, adenovirus, para-influenza and rhinoviruses."

Richard Marsden. 25 May, 2022.

Should it have taken until some, as yet unannounced , time during H2, 2023 for any form of trial activity to commence?

The possibility of an RNS emerging prior to the AGM is very slim, unless there is game changing news afoot?

There have been two RNS statements with information to investors in the last seven months.

Last December brought the summative paper, listing the Sprinter trial outcomes. Investors were well versed on that information beforehand.

Subsequently, two months ago we received the 2022 end of year statement. This signalled the end of the “partnership” trial negotiations that we were implicitly led to believe were underway? Instead we were introduced to the small scale company trialling, which will commence sometime during H2. Apparently, these are intended to provide further information towards identifying an appropriate cohort for a future Phase III trial of our host directed, broad spectrum antiviral agent? The time scale and funding of this potential trial are as yet unclear. Perhaps the consortium mentioned by Ghia are waiting in the wings to help out?

I expect that the CEO and his team will expand on the latter in the vaguest possible terms during tomorrow’s Q&A session? Isn’t this what they did last year, only to cancel their “strategy” ten months later?

My sincere gratitude to all Synairgen investors who are able to attend, and effectively represent this forum, in tomorrow’s AGM meeting. I hope that the company have more to communicate than the scraps of information that they have fed investors for sixteen months.

It is best to allow realism to dictate to our aspirations as the AGM approaches. My previous negative comment reflects my disappointment with this company’s abject failure to advance on their aspirations over the last year.

Yesterday, TommyD_19 painted a realistic picture as to what the next year might hold. Synairgen are retreating into the university spin-off space (their comfort zone), and unless an unforeseen development materialises, this is where they will remain for the time being. The share price will probably further decline as a result.

On the positive side, TFG’s 28.2% holding remains intact. A ray of sunshine on an otherwise bleak landscape.

GLALTIs.

Excellent news from the company this morning.

Additionally, given another headline today, this appears to be a good space to be invested in at the present time.

Given the right alignment, this investment should produce several multiples of the current share price. More, should a large entity swoop in!

https://www.bbc.co.uk/news/health-65988768

“I’m still not convinced they’ll be a Q&A or some excuse to cut it short”

Doc 83.

I have had serious doubts about the abilities, and attitudes towards investors, of the company’s executives for some time. They are well behind what I would deem to be a reasonable time frame to make some progress in getting their product to another trial. Sixteen months of jam tomorrow statements without measurable development is underwhelming to say the least.

Recently, I was in a toy shop with our youngest family member. When he was offered a Buzz Lightyear toy (on 60% discount) as an extra gift, he immediately declined. When asked “Why not?” he replied “Not cool!”. I have a similar sentiments about Synairgen’s version of the Pixar superhero.

Synairgen’s AGM onThursday 29 is not included in London South East’s long list* of AGMs scheduled for the coming week? This is most probably an oversight on the part of LSE?

* From LSE’s ‘Week ahead’ newsletter received yesterday evening.

TommyD_19.

All investors will agree with you about these most pressing issues. We have patiently waited for a significant update since the last AGM. As yet this hasn’t materialised, although the goalposts have since been shifted.

Achieving targeted data leading to a Phase III trial is now the company’s primary aim, and should command their exclusive focus?

It is therefore disconcerting that in the absence of progress, the board have issued a resolution for additional retrospective remuneration? It is not the amount that I question, but the priorities of the BOD and the message that it sends to investors?

Mr. Shaw holds a significant shareholding in Synairgen. Should the company progress towards bringing SNG001 to market, he will be amply rewarded, as will all Synairgen investors. I sincerely hope that we will receive some indication that progress is being made during the next week.